Although many doctors are skeptical about recommending medical marijuana for patients with psychosis, it turns out one of its components can constitute a revolutionary treatment for them. A team of researchers developed a clinical trial on cannabidiol (CBD), and discovered it has the opposite effects the psychoactive component THC.
Medical marijuana wasn’t usually prescribed for psychosis
Researchers found medical marijuana was effective for many diseases and ailments. However, they refrained from prescribing it to patients with psychosis. It’s well known that cannabis might cause anxiety and paranoia, mainly because of THC. Therefore, it seemed impossible that the plant could treat hallucinations.
However, CBD is different. This substance is not psychoactive, meaning that it doesn’t cause the typical ‘high’ feelings associated with cannabis consumption. Also, it’s widely used in various treatments. Therefore, researchers decided to test it as therapy for mental health conditions, including psychosis, epilepsy, or other neurological diseases.
CBD works as a great additional therapy to antipsychotics
The typical treatment recommended for the hallucinations and paranoia associated with psychosis are antipsychotic drugs. However, they aren’t always effective, and can often lead to the development of side effects. This medicine blocks the dopamine receptors, but dopamine isn’t the only one affected in this condition.
Therefore, researchers decided to test CBD and target different neurotransmitters. They selected 83 patients coming from countries like UK, Poland, and Romania, and split them in two groups. One was given CBD, while the second received a placebo. The first group saw an improvement in their condition, as well as in their cognitive abilities.
However, all patients continued taking their antipsychotic medication as the trial lasted. This means CBD can works as an additional treatment to the traditional one. However, the findings are still significant, and might offer a great improvement to the classical psychosis treatments. The study was published in the American Journal of Psychiatry.
Image Source: Max Pixel